Fund moves

Abbott Laboratories (ABT): Aviva PLC added to its stake +36K shares

Aviva PLC added to its stake in Abbott Laboratories, per its Q4 2025 13F.

2.28M
Shares reported · +36K vs prior quarter
0.48%
Disclosed portfolio weight
$286M
Reported value
Holdings as of
Dec 31, 2025
Filed
Feb 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  2. Nov 18, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  3. Dec 4, 2025Congress · 1 personMembers of Congress: 2 sales
  4. Dec 8, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  5. Dec 17, 2025FDAFDA device clearance: Amplatzer Piccolo™ Delivery System (9-PDS-04F-045)
  6. Dec 18, 2025FDAFDA device clearance: Assert-IQ (DM5100)
  7. Dec 18, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  8. Dec 19, 2025FDAFDA device approval: Volt™ PFA System
  9. Dec 19, 2025CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  10. Jan 22, 2026Company filing · Form 8-K · ResultsReported its results
  11. Jan 23, 2026Insider · First insider buy since Feb 2021CEO purchased ~$2.01M of ABT shares in the open market
  12. Jan 29, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  13. Feb 4, 2026Insider · 1 personInsiders: 2 purchases (~$1.1M)
  14. Feb 10, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000

What came next

  1. Feb 13, 2026FDAFDA device clearance: Armada™ 14 NC PTA Catheter
  2. Feb 20, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
  3. Feb 23, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  4. Mar 2, 2026Insider · 6 peopleInsiders: 6 sales (~$485K)
  5. Mar 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  6. Mar 13, 2026FDAFDA device clearance: Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80
  7. Mar 19, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  8. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  9. Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
  10. Apr 16, 2026FDAFDA device clearance: Disposable Radiofrequency Cannula
  11. Apr 16, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
  12. Apr 20, 2026FDAFDA device clearance: EnSite™ X EP System
  13. Apr 23, 2026Insider · 1 day before an 8-KCFO purchased ~$201K of ABT shares in the open market
  14. Apr 24, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.”
  15. Apr 24, 2026FDAFDA device clearance: OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001)
  16. Apr 24, 2026FDAFDA device clearance: Amplatzer TorqVue Delivery System
  17. Apr 27, 2026Insider · Their largest buy since 2018Director purchased ~$927K of ABT shares in the open market
  18. Apr 28, 2026FDAFDA device clearance: Anti-HCV Next
  19. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  20. May 12, 2026FDARecall: Merlin" Patient Care System (PCS) software Merlin" PCS 3650 programmer Model 3330 software
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

How this filing works

Explore the data

Common questions

What does this filing report about Abbott Laboratories (ABT) stock?

Aviva PLC added to its stake in Abbott Laboratories, per its Q4 2025 13F. Now 2.28M shares, $286M reported value, 0.48% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Dec 31, 2025. Filed: Feb 12, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Abbott Laboratories recently?

For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABT page.

Does this mean ABT stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Abbott Laboratories

Everything OQRO holds on this company is on its ABT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data